Systemic Therapy for Mutation-Driven NSCLC

Semin Radiat Oncol. 2021 Apr;31(2):140-148. doi: 10.1016/j.semradonc.2020.11.011.


Lung cancer is the leading cause of cancer deaths worldwide, and patients with nonsmall cell lung cancer have traditionally had a poor prognosis. An improved understanding of targetable oncogenic molecular alterations has led to a growing number of effective and first-line therapies in targeted patient populations. This review provides an overview of systemic therapy options available for patients with mutation-driven nonsmall cell lung cancer, as well as a discussion of data regarding safety when combined with radiation therapy.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / radiotherapy
  • Humans
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / radiotherapy
  • Molecular Targeted Therapy
  • Mutation